358 research outputs found
Can biogas digesters help to reduce deforestation in Africa?
Acknowledgements The authors are grateful for financial support for this work in part from the UK Department for International Development (DFID) New and Emerging Technologies Research Call, and in part from the EU under the REDD-ALERT (Reducing Emissions from Deforestation and Degradation from Alternative Land Uses in Rainforests of the Tropics) project, Grant agreement number 226310. The authors thank Dr Hoang Viet Anh, Dr Suyanto and Mr. Gamma Galudra for their input on the manuscript.Peer reviewedPostprin
Differential Expression of Two 1-Aminocyclopropane-1-Carboxylic Acid Oxidase Genes in Broccoli after Harvest
Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review
The COVID-19 pandemic, caused by SARS-CoV-2, continues to impact global health regarding both morbidity and mortality. Although SARS-CoV-2 primarily causes acute respiratory distress syndrome (ARDS), the virus interacts with and influences other organs and tissues, including blood vessel endothelium, heart, gastrointestinal tract, and brain. We are learning much about the pathophysiology of SARS-CoV-2 infection; however, we are just beginning to study and understand the long-term and chronic health consequences. Since the pandemic’s beginning in late 2019, older adults, those with pre-existing illnesses, or both, have an increased risk of contracting COVID-19 and developing severe COVID-19. Furthermore, older adults are also more likely to develop the neurodegenerative disorder Parkinson’s disease (PD), with advanced age as the most significant risk factor. Thus, does SARS-CoV-2 potentially influence, promote, or accelerate the development of PD in older adults? Our initial focus was aimed at understanding SARS-CoV-2 pathophysiology and the connection to neurodegenerative disorders. We then completed a literature review to assess the relationship between PD and COVID-19. We described potential molecular and cellular pathways that indicate dopaminergic neurons are susceptible, both directly and indirectly, to SARS-CoV-2 infection. We concluded that under certain pathological circumstances, in vulnerable persons-with-Parkinson’s disease (PwP), SARS-CoV-2 acts as a neurodegenerative enhancer to potentially support the development or progression of PD and its related motor and non-motor symptoms
Spectroscopic Target Selection in the Sloan Digital Sky Survey: The Quasar Sample
We describe the algorithm for selecting quasar candidates for optical
spectroscopy in the Sloan Digital Sky Survey. Quasar candidates are selected
via their non-stellar colors in "ugriz" broad-band photometry, and by matching
unresolved sources to the FIRST radio catalogs. The automated algorithm is
sensitive to quasars at all redshifts lower than z=5.8. Extended sources are
also targeted as low-redshift quasar candidates in order to investigate the
evolution of Active Galactic Nuclei (AGN) at the faint end of the luminosity
function. Nearly 95% of previously known quasars are recovered (based on 1540
quasars in 446 square degrees). The overall completeness, estimated from
simulated quasars, is expected to be over 90%, whereas the overall efficiency
(quasars:quasar candidates) is better than 65%. The selection algorithm targets
ultraviolet excess quasars to i^*=19.1 and higher-redshift (z>3) quasars to
i^*=20.2, yielding approximately 18 candidates per square degree. In addition
to selecting ``normal'' quasars, the design of the algorithm makes it sensitive
to atypical AGN such as Broad Absorption Line quasars and heavily reddened
quasars.Comment: 62 pages, 15 figures (8 color), 8 tables. Accepted by AJ. For a
version with higher quality color figures, see
http://archive.stsci.edu/sdss/quasartarget/RichardsGT_qsotarget.preprint.p
An Erupting Classical Nova in a Globular Cluster of M87
Only one certain classical nova eruption has ever been detected inside a
globular cluster - nova 1860 A.D. (T Sco) in M80. During a survey of M87 we
have detected an erupting star coincident (to within 0.08 pixels) with a
globular cluster of that giant elliptical galaxy. We are able to discount
variables in the foreground or background of M87. The light curve and color of
the erupting star match those expected for a nova at the distance of M87. The
chance superposition of an M87 field nova on the globular cluster is very
unlikely but cannot be completely ruled out.Our detection hints at a globular
cluster nova frequency novae/cluster/year, much higher than
previous observations have suggested
Physical and dynamical properties of the main belt triple asteroid (87) Sylvia
We present the analysis of high angular resolution observations of the triple
Asteroid (87) Sylvia collected with three 8-10 m class telescopes (Keck, VLT,
Gemini North) and the Hubble Space Telescope. The moons' mutual orbits were
derived individually using a purely Keplerian model. We computed the position
of Romulus, the outer moon of the system, at the epoch of a recent stellar
occultation which was successfully observed at less than 15 km from our
predicted position, within the uncertainty of our model. The occultation data
revealed that the Moon, with a surface-area equivalent diameter
Ds=23.10.7km, is strongly elongated (axes ratio of
2.70.32.70.3), significantly more than single asteroids of similar
size in the main-belt. We concluded that its shape is probably affected by the
tides from the primary. A new shape model of the primary was calculated
combining adaptive-optics observations with this occultation and 40 archived
light-curves recorded since 1978. The difference between the
J2=0.024-0.009+0.016 derived from the 3-D shape model assuming an homogeneous
distribution of mass for the volume equivalent diameter Dv=27310km primary
and the null J2 implied by the Keplerian orbits suggests a non-homogeneous mass
distribution in the asteroid's interior
Nucleotide Sequence of a cDNA Clone Encoding 1-Aminocyclopropane-1-Carboxylic Acid Synthase from Broccoli
Nucleotide Sequence of a cDNA Clone from Broccoli with High Identity with the PSST Subunit of NADH:Ubiquinone Oxidoreductase
Photometric Calibration of the Swift Ultraviolet/Optical Telescope
We present the photometric calibration of the Swift UltraViolet/Optical
Telescope (UVOT) which includes: optimum photometric and background apertures,
effective area curves, colour transformations, conversion factors for count
rates to flux, and the photometric zero points (which are accurate to better
than 4 per cent) for each of the seven UVOT broadband filters. The calibration
was performed with observations of standard stars and standard star fields that
represent a wide range of spectral star types. The calibration results include
the position dependent uniformity, and instrument response over the 1600-8000A
operational range. Because the UVOT is a photon counting instrument, we also
discuss the effect of coincidence loss on the calibration results. We provide
practical guidelines for using the calibration in UVOT data analysis. The
results presented here supersede previous calibration results.Comment: Minor improvements after referees report. Accepted for publication in
MNRA
Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock. The VANISH Randomized Clinical Trial
IMPORTANCE: Norepinephrine is currently recommended as the first-line vasopressor in septic shock; however, early vasopressin use has been proposed as an alternative. OBJECTIVE: To compare the effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock. DESIGN, SETTING, AND PARTICIPANTS: A factorial (2×2), double-blind, randomized clinical trial conducted in 18 general adult intensive care units in the United Kingdom between February 2013 and May 2015, enrolling adult patients who had septic shock requiring vasopressors despite fluid resuscitation within a maximum of 6 hours after the onset of shock. INTERVENTIONS: Patients were randomly allocated to vasopressin (titrated up to 0.06 U/min) and hydrocortisone (n = 101), vasopressin and placebo (n = 104), norepinephrine and hydrocortisone (n = 101), or norepinephrine and placebo (n = 103). MAIN OUTCOMES AND MEASURES: The primary outcome was kidney failure-free days during the 28-day period after randomization, measured as (1) the proportion of patients who never developed kidney failure and (2) median number of days alive and free of kidney failure for patients who did not survive, who experienced kidney failure, or both. Rates of renal replacement therapy, mortality, and serious adverse events were secondary outcomes. RESULTS: A total of 409 patients (median age, 66 years; men, 58.2%) were included in the study, with a median time to study drug administration of 3.5 hours after diagnosis of shock. The number of survivors who never developed kidney failure was 94 of 165 patients (57.0%) in the vasopressin group and 93 of 157 patients (59.2%) in the norepinephrine group (difference, -2.3% [95% CI, -13.0% to 8.5%]). The median number of kidney failure-free days for patients who did not survive, who experienced kidney failure, or both was 9 days (interquartile range [IQR], 1 to -24) in the vasopressin group and 13 days (IQR, 1 to -25) in the norepinephrine group (difference, -4 days [95% CI, -11 to 5]). There was less use of renal replacement therapy in the vasopressin group than in the norepinephrine group (25.4% for vasopressin vs 35.3% for norepinephrine; difference, -9.9% [95% CI, -19.3% to -0.6%]). There was no significant difference in mortality rates between groups. In total, 22 of 205 patients (10.7%) had a serious adverse event in the vasopressin group vs 17 of 204 patients (8.3%) in the norepinephrine group (difference, 2.5% [95% CI, -3.3% to 8.2%]). CONCLUSIONS AND RELEVANCE: Among adults with septic shock, the early use of vasopressin compared with norepinephrine did not improve the number of kidney failure-free days. Although these findings do not support the use of vasopressin to replace norepinephrine as initial treatment in this situation, the confidence interval included a potential clinically important benefit for vasopressin, and larger trials may be warranted to assess this further. TRIAL REGISTRATION: clinicaltrials.gov Identifier: ISRCTN 20769191
- …